Close Menu

product launch

Microba currently offers a direct-to-consumer gut microbiome profile product and plans to release additional products for clinical and research use cases.

The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.

The company has begun piloting the software, which is targeted towards bioinformatics companies and clinical laboratories, with early adopters ahead of the planned launch.

Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform, while Genapsys resurfaced with an update on its portable sequencing platform.

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.

Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.

The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.

The planned product, which will target drug-development companies, uses machine learning techniques to predict the outcomes and likelihood of success of clinical trials.

The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.